Gabelli Maintains a 'Hold' on Netflix (NFLX); Three Key Risks
Tweet
Share
E-mailGet Alerts NFLX Hot Sheet
Price: $75.59 -0.77%
Rating Summary:
58 Buy, 25 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 7 | New: 7
Rating Summary:
58 Buy, 25 Hold, 2 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 3 | Down: 7 | New: 7
Join SI Premium – FREE
Gabelli maintains a 'Hold' on Netflix (NASDAQ: NFLX).
Gabelli analyst, said, "We see three key risks: 1) increased competition from advanced TV products provided by traditional MVPDs (Comcast xfinity, HBO GO) and other internet video providers (Hulu & You Tube) 2) rising expenses from content costs and 3) challenges replicating its US streaming business in international markets without the benefit of an incumbent by-mail business. Given these risks, we do not see a sufficient margin of safety to buy shares."
"We estimate Netflix will generate 2012 revenue, EBITDA and EPS of $3.7 billion, $75 million, and $0.05 per share, respectively."
For an analyst ratings summary and ratings history on Netflix click here. For more ratings news on Netflix click here.
Shares of Netflix closed at $80.39 yesterday.
Gabelli analyst, said, "We see three key risks: 1) increased competition from advanced TV products provided by traditional MVPDs (Comcast xfinity, HBO GO) and other internet video providers (Hulu & You Tube) 2) rising expenses from content costs and 3) challenges replicating its US streaming business in international markets without the benefit of an incumbent by-mail business. Given these risks, we do not see a sufficient margin of safety to buy shares."
"We estimate Netflix will generate 2012 revenue, EBITDA and EPS of $3.7 billion, $75 million, and $0.05 per share, respectively."
For an analyst ratings summary and ratings history on Netflix click here. For more ratings news on Netflix click here.
Shares of Netflix closed at $80.39 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- HSBC Starts Keymed Biosciences Inc (2162:HK) at Buy
- Jefferies Downgrades Pro Medicus (PME:AU) (PMCUF) to Hold
- Goldman Sachs Starts Contemporary Amperex Technology Co Ltd (300750:CH) at Buy
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
HuluSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
